drugset
drugset / Trial / NCT03963375

Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis

NCT03963375 ↗

Phase 4 Completed 47 enrolled Washington University School of Medicine EMD Serono · collab
RandomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to better understand the mechanism of action (MoA) of cladribine tablets by exploring the effect on central nervous system (CNS) and blood biomarkers relevant in the relapsing forms of multiple sclerosis (RMS; to include relapsing-remitting MS \[RRMS\] or active secondary progressive MS).

Timeline

Start
2019-10-28
Primary completion
2025-05-27
Completion
2025-05-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Cladribine Small molecule 3.5 mg/kg —

Indications

relapsing-remitting multiple sclerosis